Language

Chinese English

Home page

CPIC 2026 | TONACEA and NAPPA Officially Sign Strategic Cooperation Agreement

Apr 22,2026

Boston & Beijing–April 20, 2026–Against the backdrop of accelerating integration in global biopharmaceutical innovation, TONACEA, a renowned industrial ecosystem platform for biopharmaceutical innovation in China, has officially entered into a strategic cooperation with NAPPA (North American Pharmaceutical Professionals Alliance).

Guided by the China–U.S. Dual Engine strategy, the two parties will jointly advance a global-oriented biopharmaceutical innovation collaboration platform, promote efficient cross-border resource integration, accelerate the translation of innovative achievements, and build a sustainable new paradigm for industrial cooperation.

This cooperation marks a key step in the global ecological layout of both parties. Leveraging TONACEA's profound capabilities in China's industrial integration and full-chain resources, combined with NAPPA's advantages in cross-border business matchmaking rooted in North America and covering the globe, the two sides will jointly build an open, collaborative and scalable biopharmaceutical industrial platform. The platform will connect core stakeholders across the entire industrial chain, including pharmaceutical companies, biotech firms, investment institutions, research institutes and service providers, to continuously unleash innovation potential and commercial value.

In accordance with the cooperation agreement, the two parties will carry out in-depth cooperation in three core areas:

01、Joint Development of Brand Events

The two parties will mutually support conferences and events hosted by each other, jointly develop China–U.S. online live broadcasts, international forums and diversified exchange scenarios, build a globally influential exchange and cooperation platform for biopharmaceuticals between China and the United States, and improve industrial connectivity efficiency and brand value.

02、Innovative Drug BD Global Expansion

Linking global MNCs and overseas investment institutions, the two parties will build an end-to-end acceleration mechanism from project presentation, business matchmaking and clinical development to commercialization, help Chinese innovative drugs achieve BD overseas and NewCo offshore expansion, and improve the global development efficiency of high-potential innovative assets.

03、Resource Interconnection and Industrial Linkage

Centering on the entire biopharmaceutical industrial chain, the two parties will integrate key resources such as scientific research innovation, biopharmaceuticals, AI technology, investment and financing, CRO/CDMO and supply chain, build a cross-regional and cross-field ecological circle, promote efficient resource interconnection, and accelerate in-depth integration of Chinese and U.S. industries.

Dr. Zengjiang Cheng, Founder and Chairman of TONACEA, stated:This cooperation fully embodies our mission of ‘Connecting the Global Ecosystem and Empowering Biopharmaceutical Innovation and Growth’. Through in-depth cooperation with NAPPA, we jointly built a key service platform connecting the Chinese and U.S. markets, continuously create high-quality cross-border cooperation opportunities and release industrial synergy value.

John Xu, Founder of NAPPA, stated:We are honored to be TONACEA's official partner in North America. TONACEA is a leading indicator in China's biopharmaceutical innovation sector. This cooperation directly connects the world's largest biopharmaceutical market with China's innovation ecosystem. We look forward to accelerating the delivery of more innovative achievements to benefit patients worldwide through comprehensive strategic cooperation.

As a key implementation of the cooperation, NAPPA will host a dedicated session at the inaugural China Pharmaceutical Innovation Conference (CPIC 2026), focusing on overseas transfer of projects from Chinese enterprises, as well as fields and projects of key interest to overseas enterprises and investment institutions, to build a precise and efficient cross-border matchmaking bridge.

ABOUT NAPPA

NAPPA (North American Pharmaceutical Professionals Alliance) is an organization founded in Boston with the mission of bridging biopharmaceutical resources between overseas markets and China, and fostering business collaboration within the global biomedical sector. Rooted in North America yet globally connected, NAPPA is dedicated to establishing a comprehensive one-stop business matchmaking platform for the broader healthcare industry. Leveraging the extensive international resource networks of its members, we prioritize facilitating efficient connections between overseas biopharmaceutical enterprises and the Chinese market.

Furthermore, through deep engagement and active participation, we drive the concrete implementation of cross-border collaborations, thereby ensuring mutually beneficial outcomes for all parties involved. Concurrently, for individuals and institutions within the healthcare sector that possess clear collaboration needs but face resource constraints, NAPPA offers precise resource matching and operational support, empowering them to swiftly identify suitable partners and accelerate both project advancement and value realization. Currently, NAPPA maintains designated representatives across various countries and regions—including Europe, Australia, Singapore, Taiwan, Japan, South Korea, and Hong Kong—who are available to assist in connecting global resources; additionally, we have established local liaisons in major cities throughout both the United States and China.

Dr. John Xu, NAPPA's Founding President, personally commands an extensive global network of biopharmaceutical resources and serves as an advisor to over a dozen U.S.-based investment funds and biomedical companies; he also maintains excellent relationships with numerous major international pharmaceutical corporations.

This upcoming conference will feature a dedicated NAPPA session, specifically focused on facilitating the international licensing and transfer of projects from Chinese companies, as well as highlighting specific projects and therapeutic areas of interest to overseas companies and investment funds. We warmly invite all interested parties to attend.

To contact NAPPA: lucai@nappa.bio

info@NAPPA.bio

About TONACEA

TONACEA is a premier ecosystem platform in China's biopharmaceutical innovation sector. With over 20 years of deep commitment to advancing China's novel drug development, it has evolved into a key organizational force driving the country's pharmaceutical innovation, serving as a core hub connecting multinational pharmaceutical companies with local innovation.

TONACEA brings together multinational pharmaceutical companies, biotech firms, investment institutions, research institutes, and regulatory experts, establishing a high-end professional network and knowledge-sharing ecosystem that spans the entire R&D value chain. Its business scope encompasses industry summits, technical forums, customized corporate training, media communications, and strategic consulting. With branches in Beijing, Shanghai, Suzhou, Guangzhou, Shenzhen, and other cities, TONACEA has built a nationwide operational network.

The TONACEA WeChat official account and video channel consistently deliver in-depth industry insights, with its perspectives frequently cited by investors and media, earning recognition as a trusted "authoritative source" within the industry. The "Huashan Award," co-launched by the platform, sets a benchmark for the globalization of Chinese innovative drugs and empowers local enterprises to step onto the world stage.